23694-81-7

Basic information

• Product Name: 1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol
• Synonyms: 1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol;mepindolol;1-(Isopropylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]-2-propanol;1-[(1-Methylethyl)aMino]-3-[(2-Methyl-1H-indol-4-yl)oxy]-2-propanol;rac Mepindolol;RaceMic Mepindolol;1-[(1-Methylethyl-d7)aMino]-3-[(2-Methyl-1H-indol-4-yl)oxy]-2-propanol;1-[(Isopropyl-d7)aMino]-3-[(2-Methylindol-4-yl)oxy]-2-propanol
• CAS NO: 23694-81-7
• Molecular Formula: C₁₅H₂₂N₂O₂
• Molecular Weight: 262.34738
• EINECS: 245-831-1
• Product Categories: Aromatics;Heterocycles;Indole Derivatives;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 23694-81-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 100-102° (Seeman). Also reported as 95-97° (Troxler)
• Boiling Point: 469.9°Cat760mmHg
• Flash Point: 238°C
• Appearance: /
• Density: 1.131g/cm³
• Vapor Pressure: 1.24E-09mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly, Heated, Sonicated), Methanol (Slightly)
• PKA: pKa 8.90 (Uncertain)
• CAS DataBase Reference: 1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol(23694-81-7)
• EPA Substance Registry System: 1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol(23694-81-7)

Safety Data

• Hazardous Substances Data: 23694-81-7(Hazardous Substances Data)

Usage

Description

1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol is a complex organic compound characterized by its isopropylamino and methyl-indol-4-yloxy functional groups. It is an off-white solid with unique chemical properties that make it suitable for various applications in different industries.

Uses

Used in Pharmaceutical Industry:
1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol is used as a non-selective β-adrenoceptor blocking agent for the treatment of glaucoma. Its ability to block β-adrenoceptors helps in reducing intraocular pressure, which is a key factor in managing glaucoma.
Used in Chemical Research:
1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol can be utilized in chemical research and development due to its unique structural features. It may serve as a starting material or intermediate in the synthesis of various pharmaceuticals, agrochemicals, or other specialty chemicals.
Used in Drug Delivery Systems:
Similar to gallotannin, 1-[isopropylamino]-3-[(2-methyl-indol-4-yl)oxy]-2-propanol could potentially be employed in the development of novel drug delivery systems. Its chemical properties may allow for the creation of carriers or enhancers that improve the delivery, bioavailability, and therapeutic outcomes of various drugs.

InChI:InChI=1/C15H22N2O2/c1-10(2)16-8-12(18)9-19-15-6-4-5-14-13(15)7-11(3)17-14/h4-7,10,12,16-18H,8-9H2,1-3H3

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.